Lennox-Gastaut syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 24 Jun 2026 04:14:47 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Lennox-Gastaut syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the effectiveness and safety of clemizole hydrochloride as an additional treatment for patients with Lennox-Gastaut syndrome https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-clemizole-hydrochloride-as-an-additional-treatment-for-patients-with-lennox-gastaut-syndrome/ Thu, 30 Apr 2026 13:08:56 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-clemizole-hydrochloride-as-an-additional-treatment-for-patients-with-lennox-gastaut-syndrome/ This study aims to evaluate the efficacy of clemizole hydrochloride compared with a placebo in individuals living with Lennox-Gastaut Syndrome. This condition is a rare type of epilepsy, which is a neurological disorder characterized by recurrent, unprovoked seizures. The research focuses on whether adding the study medication to existing treatments can help manage the symptoms associated with this syndrome.

Participants will be assigned to receive either clemizole hydrochloride in the form of an oral solution or a placebo. The study is designed as a double-blind trial, meaning that neither the participants nor the researchers will know which substance is being administered during the process. The course of the study involves different stages, including a period where the dose is gradually adjusted, followed by a maintenance period where the treatment is continued.

]]> Long-Term Safety Study of Fenfluramine Hydrochloride for Seizures in Patients with Dravet or Lennox-Gastaut Syndrome https://clinicaltrials.eu/trial/long-term-safety-study-of-fenfluramine-hydrochloride-for-seizures-in-patients-with-dravet-or-lennox-gastaut-syndrome/ Wed, 29 Apr 2026 14:59:25 +0000 https://clinicaltrials.eu/trial/long-term-safety-study-of-fenfluramine-hydrochloride-for-seizures-in-patients-with-dravet-or-lennox-gastaut-syndrome/ This clinical trial is focused on studying the long-term safety of a medication called fenfluramine hydrochloride, also known by its code name ZX008. The study is designed for individuals with rare seizure disorders, specifically Dravet syndrome and Lennox-Gastaut syndrome. These are types of epileptic encephalopathies, which are severe forms of epilepsy that begin in childhood and are characterized by frequent seizures and developmental delays.

The purpose of the study is to assess how safe and tolerable fenfluramine hydrochloride is when used over a long period as an additional treatment for seizures. Participants in the study will take the medication in the form of an oral solution. The study will monitor the participants’ health and any side effects they may experience while taking the medication. This includes regular check-ups and various health assessments to ensure the safety of the participants.

Throughout the study, participants will continue to receive the medication and will be observed for any changes in their condition. The study aims to provide valuable information on the long-term use of fenfluramine hydrochloride in managing seizures associated with these rare disorders. This research is important for understanding how the medication can help improve the quality of life for those affected by these challenging conditions.

]]> Study on Long-Term Safety of Soticlestat for Patients with Dravet or Lennox-Gastaut Syndromes https://clinicaltrials.eu/trial/study-on-long-term-safety-of-soticlestat-for-patients-with-dravet-or-lennox-gastaut-syndromes/ Wed, 29 Apr 2026 14:57:00 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-of-soticlestat-for-patients-with-dravet-or-lennox-gastaut-syndromes/ This clinical trial is focused on studying the long-term safety and tolerability of a medication called soticlestat for individuals with Dravet Syndrome and Lennox-Gastaut Syndrome. These are both rare forms of epilepsy that begin in childhood and are characterized by frequent seizures. The medication, known by its code name TAK-935, is being tested as an additional treatment to standard care, which may include anti-seizure medications, vagus nerve stimulation, or specific diets like the ketogenic or modified Atkins diet.

The purpose of the study is to assess how well patients tolerate soticlestat over a long period. Participants in the study will take the medication in tablet form by mouth. The study will last up to 52 weeks, during which time participants will be monitored for any side effects and changes in their health. The study will also look at changes in seizure frequency and other health indicators, such as growth and development in children.

This trial is an extension of previous studies, meaning it includes participants who have already been involved in earlier research phases. The study aims to provide more information on the long-term use of soticlestat, helping to determine its safety and effectiveness as a treatment option for those living with Dravet Syndrome and Lennox-Gastaut Syndrome.

]]> Study on Carisbamate for Treating Seizures in Children and Adults with Lennox-Gastaut Syndrome https://clinicaltrials.eu/trial/study-on-carisbamate-for-treating-seizures-in-children-and-adults-with-lennox-gastaut-syndrome/ Wed, 29 Apr 2026 14:28:11 +0000 https://clinicaltrials.eu/trial/study-on-carisbamate-for-treating-seizures-in-children-and-adults-with-lennox-gastaut-syndrome/ This clinical trial is focused on studying Lennox-Gastaut syndrome (LGS), a type of epilepsy that causes multiple types of seizures and developmental delays in children and adults. The study is testing a treatment called Carisbamate, also known by its code name YKP509, which is taken as an oral suspension. The purpose of the study is to evaluate how effective and safe Carisbamate is when used alongside other treatments to reduce the number of specific seizures, such as tonic, atonic, and tonic-clonic seizures, in people with LGS.

Participants in the study will be randomly assigned to receive either Carisbamate or a placebo, which looks like the treatment but does not contain the active medicine. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The study will include both children and adults aged 4 to 55 years who have been diagnosed with LGS. Participants will continue their current anti-seizure medications while taking part in the study.

The trial will last for a period of time during which participants will be monitored for changes in the frequency of their seizures. There is also an optional open-label extension, where all participants can receive Carisbamate after the initial study period. The main goal is to see if Carisbamate can significantly reduce the number of drop seizures, which are seizures that can lead to falls or injuries. Participants and their caregivers will be asked to keep a diary of seizures to help track any changes during the study.

]]> Study on Soticlestat for Children and Adults with Dravet or Lennox-Gastaut Syndrome Previously Treated with Fenfluramine https://clinicaltrials.eu/trial/study-on-soticlestat-for-children-and-adults-with-dravet-or-lennox-gastaut-syndrome-previously-treated-with-fenfluramine/ Wed, 29 Apr 2026 14:26:09 +0000 https://clinicaltrials.eu/trial/study-on-soticlestat-for-children-and-adults-with-dravet-or-lennox-gastaut-syndrome-previously-treated-with-fenfluramine/ This clinical trial is focused on studying the effects of a medication called soticlestat in individuals with Dravet Syndrome or Lennox-Gastaut Syndrome. These are both rare forms of epilepsy that begin in childhood and are characterized by frequent seizures. The study is designed to evaluate whether soticlestat can help reduce seizures in patients who have previously been treated with another medication called fenfluramine.

The purpose of the study is to assess the effectiveness and safety of soticlestat. Participants in the study will take soticlestat in the form of a tablet, which is taken orally. The study will last for up to 52 weeks, during which time participants will be monitored to see how their seizure frequency changes. Some participants may receive a placebo, which is a tablet that looks like the medication but does not contain the active substance.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their condition. The goal is to determine if soticlestat can provide a beneficial treatment option for those living with Dravet Syndrome or Lennox-Gastaut Syndrome, especially for those who have already tried fenfluramine. This study is an important step in finding new ways to manage these challenging conditions.

]]> Study on Cannabidiol Oral Solution for Infants with Tuberous Sclerosis, Dravet Syndrome, or Lennox-Gastaut Syndrome Experiencing Uncontrolled Seizures https://clinicaltrials.eu/trial/study-on-cannabidiol-oral-solution-for-infants-with-tuberous-sclerosis-dravet-syndrome-or-lennox-gastaut-syndrome-experiencing-uncontrolled-seizures/ Wed, 29 Apr 2026 14:25:55 +0000 https://clinicaltrials.eu/trial/study-on-cannabidiol-oral-solution-for-infants-with-tuberous-sclerosis-dravet-syndrome-or-lennox-gastaut-syndrome-experiencing-uncontrolled-seizures/ This clinical trial is focused on studying the effects of a treatment for children with certain types of epilepsy, specifically Tuberous Sclerosis Complex, Dravet Syndrome, and Lennox-Gastaut Syndrome. These conditions are known for causing seizures that are difficult to control with standard treatments. The study will use a medication called Cannabidiol, which is provided as an oral solution known by the code name GWP42003-P. Cannabidiol is a chemical compound that is being tested to see if it can help reduce the frequency of seizures in these young patients.

The purpose of the study is to evaluate the safety and effectiveness of this treatment over a period of 52 weeks. Participants will receive the Cannabidiol oral solution in addition to their current seizure medications. The study will monitor how the body processes the medication and its effects on seizure frequency. The trial is open-label, meaning all participants will receive the active treatment, and there is no placebo group. The study will involve regular check-ups to assess the health and development of the participants, as well as to monitor any side effects or changes in seizure patterns.

Throughout the study, caregivers will be asked to keep a diary of the participant’s seizures to help researchers understand how well the treatment is working. The study aims to provide valuable information on whether Cannabidiol can be a safe and effective addition to existing treatments for these challenging epilepsy conditions in young children.

]]> Study on Long-Term Safety of Soticlestat for Adults and Children with Developmental Epileptic Encephalopathies https://clinicaltrials.eu/trial/study-on-long-term-safety-of-soticlestat-for-adults-and-children-with-developmental-epileptic-encephalopathies/ Wed, 29 Apr 2026 14:23:27 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-of-soticlestat-for-adults-and-children-with-developmental-epileptic-encephalopathies/ This clinical trial is focused on studying the long-term safety and tolerability of a medication called soticlestat (also known by its code name TAK-935). The study is designed for individuals with certain types of rare epilepsies, specifically Developmental Epileptic Encephalopathies. These include conditions such as Dravet Syndrome, Lennox Gastaut Syndrome, CDKL5 Deficiency Disorder, and Chromosome 15 Duplication Syndrome. The purpose of the study is to see how well soticlestat can be tolerated when used alongside other treatments for seizures, such as anti-seizure medications, a vagal nerve stimulator, or special diets like the ketogenic or modified Atkins diet.

Participants in this study will take soticlestat in the form of a tablet, which is taken orally. The study will follow participants over a period to monitor their health and any side effects they might experience. The maximum daily dose of soticlestat is 600 milligrams, and the treatment period can last up to 96 weeks. Throughout the study, researchers will keep track of any adverse events, changes in behavior, and other health indicators to ensure the safety of the participants.

This study is an extension of previous research, meaning that participants have already been involved in earlier studies of soticlestat. The goal is to gather more information about how the medication affects people over a longer period. By doing so, researchers hope to better understand the potential benefits and risks of using soticlestat as a treatment for these rare epileptic conditions.

]]>